STOCK TITAN

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Celyad Oncology (Euronext & Nasdaq: CYAD) announced it will report its full year 2021 financial and operational results on March 24. Following the results, management will host a conference call on March 25 at 1 p.m. CET to discuss the outcomes and provide updates on recent progress and milestones. Celyad specializes in the development of CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous therapies to address various malignancies.

Positive
  • Upcoming reporting of full year 2021 financial results may provide insights into business performance.
  • Management conference call allows for direct communication on recent progress and future milestones.
Negative
  • None.

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2021 financial and operating results on the evening of Thursday, March 24th.

Following the press release, Celyad management will host a conference call on Friday, March 25th at 1 p.m. CET / 8 a.m. ET to discuss full year 2021 results and provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing +1-412-317-6060 (International), +1-866-652-5200 (United States) or +32 (0) 800-38913 (Belgium).

To access the live webcast and archived recording, visit the "Events" section of the Celyad website.

About Celyad Oncology

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-Looking Statement

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding: the KEYNOTE-B79 trial and the clinical hold. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts:

Sara Zelkovic

Communications & Investor Relations Director

Celyad Oncology

investors@celyad.com

Daniel Ferry

Managing Director

LifeSci Advisors, LLC

daniel@lifesciadvisors.com

Source: Celyad Oncology SA

FAQ

When will Celyad report its 2021 financial results?

Celyad will report its full year 2021 financial results on March 24.

What time is the Celyad conference call regarding 2021 results?

The conference call is scheduled for March 25 at 1 p.m. CET.

How can I access the Celyad conference call?

Participants can access the call by dialing +1-412-317-6060 internationally or +1-866-652-5200 in the US.

What therapies does Celyad Oncology focus on?

Celyad Oncology focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer.

What is the stock symbol for Celyad Oncology?

The stock symbol for Celyad Oncology is CYAD.

CYAD

NASDAQ:CYAD

CYAD Rankings

CYAD Latest News

CYAD Stock Data

14.24M
13.58M
0.05%
29.15%
0.58%
Biotechnology
Healthcare
Link
Belgium
Mont-Saint-Guibert